A groundbreaking new pill could help diabetic and obese patients without the common side effects associated with GLP-1 medications. Unlike popular injectable drugs like Wegovy, this experimental treatment works through a completely different mechanism, targeting metabolism in skeletal muscle rather than suppressing appetite.
How the New Drug Works
Known as GRK-biased adrenergic agonists, the medication stimulates metabolic processes within muscle tissue, improving blood sugar control and body composition. Researchers at Karolinska Institutet and Stockholm University published their findings in the journal Cell, highlighting that the drug avoids appetite suppression, muscle loss, and digestive problems frequently seen with GLP-1 therapies.
Professor Tore Bengtsson from Stockholm University stated: "Our results point to a future where we can improve metabolic health without losing muscle mass. Muscles are important in both type 2 diabetes and obesity, and muscle mass is also directly correlated with life expectancy."
Clinical Trial Results
A Phase I clinical trial involving 48 healthy volunteers and 25 people with type 2 diabetes showed that participants tolerated the treatment well. The drug is based on a laboratory-developed molecule called a β2 agonist, engineered to trigger beneficial signalling pathways in muscle without overstimulating the heart—a challenge that has historically limited such compounds.
Shane C Wright, assistant professor at Karolinska Institutet, added: "This drug represents a completely new type of treatment and has the potential to be of great importance for patients with type 2 diabetes and obesity. Our substance appears to promote healthy weight loss and, in addition, patients do not have to take injections."
Potential as Standalone or Combination Therapy
Since the new treatment works differently from GLP-1 medications, researchers believe it could be used both independently and alongside existing therapies. "This makes them valuable both as a stand-alone treatment and in combination with GLP-1 drugs," Wright explained.
The company behind the drug, Atrogi AB, will now lead a larger Phase II clinical trial. Researchers are hopeful that the promising preclinical results can be replicated in patients with type 2 diabetes or obesity.
Comparison to Approved UK Pill
This new pill differs from the one recently approved by the UK's Medicines and Healthcare products Regulatory Agency (MHRA). That tablet uses semaglutide, the same active ingredient as approved weight loss jabs, making it a GLP-1 receptor agonist. Known side effects of GLP-1s include tiredness, dizziness, hair loss, low blood sugar, and fast heart rate, affecting around one in 10 people. A rarer but serious side effect is acute pancreatitis, which can cause abdominal pain, fever, nausea, and vomiting. Anyone experiencing these symptoms should call 111. For weight concerns, speak to your GP.
